FibroBiologics Financial Statements From 2010 to 2026

FBLG Stock   0.25  0  0.68%   
FibroBiologics Common's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing FibroBiologics Common's valuation are provided below:
Market Capitalization
16.7 M
Earnings Share
(0.48)
There are over one hundred seven available fundamental signals for FibroBiologics Common Stock, which can be analyzed over time and compared to other ratios. Active traders should verify all of FibroBiologics Common Stock prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is estimated to decrease to about 1 B
Check FibroBiologics Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroBiologics Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 454.6 K, Selling General Administrative of 11.1 M or Other Operating Expenses of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.72. FibroBiologics financial statements analysis is a perfect complement when working with FibroBiologics Common Valuation or Volatility modules.
  
Build AI portfolio with FibroBiologics Stock
Check out the analysis of FibroBiologics Common Correlation against competitors.

FibroBiologics Common Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding35.8 M37.8 M33 M
Slightly volatile
Common Stock855900756.8 K
Slightly volatile
Total Assets19.9 M18.9 M4.6 M
Slightly volatile
Short and Long Term Debt Total12.7 M12.1 M3.5 M
Slightly volatile
Other Current Liabilities502.6 K529 K727.7 K
Slightly volatile
Total Current Liabilities8.5 M14.6 M4.3 M
Slightly volatile
Accounts Payable3.3 M3.1 M811.1 K
Slightly volatile
Cash16.9 M16.1 M3.7 M
Slightly volatile
Cash And Short Term Investments16.9 M16.1 M3.7 M
Slightly volatile
Liabilities And Stockholders Equity19.9 M18.9 M4.6 M
Slightly volatile
Other Current Assets293.4 K279.4 K97.6 K
Slightly volatile
Other Stockholder Equity46.2 M44 M10.2 M
Slightly volatile
Total Liabilities9.6 M15.8 M4.7 M
Slightly volatile
Net Invested Capital14.4 M13.7 M2.5 M
Slightly volatile
Short and Long Term Debt5.8 M10.5 M3.3 M
Slightly volatile
Total Current Assets17.2 M16.4 M3.8 M
Slightly volatile
Short Term Debt11.6 M11 M3.2 M
Slightly volatile
Net Receivables240 K270 K294.7 K
Slightly volatile
Non Current Liabilities Other800900982
Slightly volatile

FibroBiologics Common Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization454.6 K515.7 K884 K
Slightly volatile
Selling General Administrative11.1 M10.6 M2.8 M
Slightly volatile
Other Operating Expenses16.6 M15.8 M4.3 M
Slightly volatile
Research Development5.4 M5.2 M1.6 M
Slightly volatile
Total Operating Expenses16.6 M15.8 M4.3 M
Slightly volatile
Interest Expense17.1 K18 K53.2 K
Slightly volatile
Selling And Marketing Expenses428.4 K787.8 K224 K
Slightly volatile
Cost Of Revenue404.8 K659 K193.9 K
Slightly volatile

FibroBiologics Common Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities5.8 M10.8 M3.2 M
Slightly volatile
Total Cash From Financing Activities20.4 M19.4 M5.4 M
Slightly volatile
Change In Cash3.8 M5.5 M1.6 M
Slightly volatile
Net Borrowings11.4 M10.8 M3.2 M
Slightly volatile
Change In Working Capital421 K642.9 K263.9 K
Slightly volatile
End Period Cash Flow16.9 M16.1 M3.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.350.370.9941
Slightly volatile
Cash Per Share0.40.380.1004
Slightly volatile
Income Quality0.620.960.8543
Slightly volatile
Current Ratio0.551.010.4263
Slightly volatile
Capex Per Share0.01140.00640.0139
Slightly volatile
Interest Debt Per Share0.30.290.1002
Slightly volatile
Debt To Assets1.410.742.2254
Slightly volatile
Ebt Per Ebit0.960.731.0314
Very volatile
Total Debt To Capitalization1.290.911.8412
Slightly volatile
Quick Ratio0.551.010.4263
Slightly volatile
Cash Ratio0.530.990.395
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.171.084
Slightly volatile
Debt Ratio1.410.742.2254
Slightly volatile

FibroBiologics Common Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap756.2 M851 M928.8 M
Slightly volatile
Enterprise ValueB1.1 B958.3 M
Slightly volatile

FibroBiologics Fundamental Market Drivers

About FibroBiologics Common Financial Statements

FibroBiologics Common stakeholders use historical fundamental indicators, such as FibroBiologics Common's revenue or net income, to determine how well the company is positioned to perform in the future. Although FibroBiologics Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in FibroBiologics Common's assets and liabilities are reflected in the revenues and expenses on FibroBiologics Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in FibroBiologics Common Stock. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue659 K404.8 K

Currently Active Assets on Macroaxis

When determining whether FibroBiologics Common is a strong investment it is important to analyze FibroBiologics Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics Common's future performance. For an informed investment choice regarding FibroBiologics Stock, refer to the following important reports:
Check out the analysis of FibroBiologics Common Correlation against competitors.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Can Biotechnology industry sustain growth momentum? Does FibroBiologics have expansion opportunities? Factors like these will boost the valuation of FibroBiologics Common. Market participants price FibroBiologics higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating FibroBiologics Common demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(0.48)
Return On Assets
(1.16)
Return On Equity
(12.93)
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, FibroBiologics Common's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.